Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential
09:31pm, Thursday, 06'th Jul 2023
ImmunoGen's Q1 2023 revenue increased to $49.9 million, primarily due to sales of Elahere and an upfront fee from Vertex Pharmaceuticals. The company plans to close a $325 million public offering. The
3 Biotech Stocks to Make Your ‘Get Rich' Dreams Come True
04:43pm, Thursday, 06'th Jul 2023
Navigating the choppy waters in the biotech sphere can be daunting, which makes it a challenge to hunt for the top high return biotech stocks. The journey to market approval, encumbered by volatile cl
5 Sizzling Stocks That Are Outperformers in the Market This Year
02:11pm, Sunday, 02'nd Jul 2023
The scorching 2023 S&P 500 market rally has been red hot. As a result, we're seeing quite a few sizzling market outperformers.
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
08:13am, Monday, 26'th Jun 2023
ImmunoGen Inc. NASDAQ: IMGN is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver cancer-killin
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
04:30pm, Wednesday, 24'th May 2023
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference.
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now
12:14pm, Friday, 19'th May 2023
ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
10:00am, Friday, 19'th May 2023
The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our
Tech Titans Aren't The Only Game In Town, Consider Biotech And, Yes, Financials
09:08pm, Sunday, 14'th May 2023
The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great for Insurance companies and “hidden banks”.
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
01:42pm, Friday, 12'th May 2023
ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
08:31am, Monday, 08'th May 2023
Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for progre
ImmunoGen stock price doubles after ovarian cancer candidate Elahere aces phase 3 study
12:36pm, Wednesday, 03'rd May 2023
ImmunoGen Inc stock more than doubled after the company shared positive topline data from the Phase 3 confirmatory MIRASOL trial evaluating the safety and effectiveness of its experimental ovarian can
Why ImmunoGen Stock Is Soaring Wednesday
11:53am, Wednesday, 03'rd May 2023
The company said it anticipates asking for full approval of Elahere from the FDA. The drug was granted accelerated approval in November to treat advanced ovarian cancer.
Wall Street Analysts See a 101.92% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?
11:26am, Wednesday, 03'rd May 2023
The mean of analysts' price targets for ImmunoGen (IMGN) points to a 101.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy
Why Is ImmunoGen (IMGN) Stock Up 125% Today?
10:04am, Wednesday, 03'rd May 2023
ImmunoGen (NASDAQ: IMGN ) stock is rising higher on Wednesday after the company released results from a Phase 3 trial for treating ovarian cancer. According to a press release, the company reported po
Immunogen stock more than doubles on heavy volume after positive trial data ovarian cancer treatment
09:08am, Wednesday, 03'rd May 2023
Shares of Immunogen Inc. IMGN blasted 121.2% higher on heavy volume toward a five-year high in premarket trading Wednesday, after the biopharmaceutical company revealed positive data from a late-stage
